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Objective:Theobjectiveofthisarticleistopresentanddiscusstheclinicalcharacteristics
ofTEN(ToxicEpidermalNecrolysis)andGVHD(GraftVersusHostDisease)following
orthotopiclivertransplantation.Methods:Recentexperiencewithapatientwhosuffered
af atal desquamation syndrome within weeks of liver transplantation provides the basis
for a discussion of differential diagnosis of these two conditions. Results: TEN and
GVHDdemonstratesimilarclinicalpresentationsaswellasetiology(CD8+lymphocyte
attack on epithelial surfaces). This case demonstrates the difficulty in distinguishing
between these two conditions in this particular patient. Conclusions: Advances in the
understanding and treatment of one of these disease states may provide therapeutic
insights into the other.
We recently cared for a patient who suffered a fatal desquamation syndrome within
af ew weeks of orthotopic liver transplantation. Although the patient’s working diagnosis
wast o xic epidermal necrolysis (TEN), his history of recent liver transplant suggested the
possibility of another diagnosis: graft versus host disease (GVHD). While TEN is well
known to burn care providers, GVHD is something that many have never encountered.
Here we present the case, followed by a discussion of the clinical characteristics of both
TEN and GVHD following orthotopic liver transplantation.
CASE REPORT
A 55-year-old man presented to our hospital complaining of fever, rash, and a sore mouth.
Twenty-three days prior the patient had undergone orthotopic liver transplantation for
chronic active hepatitis C with a T1N0M0 hepatocellular carcinoma. His transplantation
was without immediate complication, and he was discharged on the following new medi-
cations: bactrim ss daily, aspirin 325 mg daily, azothioprine 100 mg daily, tacrolimus 2 mg
daily,andvalgancyclovirHCl900mgdaily.Thepatienthadbeentreatedwithantithymocyte
globulin during induction of immunosuppression.
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The patient did well until 17 days after transplant when he presented with fever. Ab-
dominopelvic computed tomography demonstrated a hepatic subcapsular hematoma, and
he was treated with piperacillin/tazobactam for a presumed infected hematoma. He was
discharged on posttransplant day 21 on oral ampicillin/sulbactam. Shortly after discharge,
he developed diffuse erythroderma, fever, and a sore mouth and returned to the hospital.
The burn service was consulted.
The patient was ill-appearing with an oral temperature of 104◦F,aheart rate of 122, a
blood pressure of 120/64 mm Hg, and a respiratory rate of 24; he had widespread macular
erythema and a few hemorrhagic bullae, as well as oropharyngeal ulceration. Nikolsky’s
sign was positive in multiple locations. He was admitted to the burn intensive care unit and
topical antimicrobials were applied to his wounds.
The patient had no known drug allergies. His past history was notable only for type
2 diabetes mellitus and ethanol dependence (abstinent for 1 year). He was taking no al-
ternative medicines. The patient’s laboratory results were notable for a serum creatinine
level of 1.4 mg/dL (increased over a normal baseline) and a white blood cell count of 0.1
with a differential showing no neutrophils. A skin biopsy revealed full-thickness epithelial
necrosis, consistent with a diagnosis of Stevens-Johnson syndrome or TEN. There was a
sparse lymphocytic infiltrate in the papillary dermis.
Althoughhisairwaywasinitiallystable,within24hoursofadmissionhewasintubated
for airway protection as his oropharyngeal mucosa began to disintegrate. Meanwhile, his
bullous erythroderma progressed until most of his epidermis had sloughed off and he
developed intermittent atrial fibrillation and a vasopressor requirement. In consultation
with infectious disease medicine and transplant surgery services, the patient was begun on
empiric vancomycin and aztreonam and all of his immunosuppressants were held except
for tacrolimus (dose adjusted down).
Overthenextseveraldays,thepatient’sconditioncontinuedtodeclinewithanuricrenal
failure and Staphylococcal/Candidal septic shock. Filgrastim failed to evoke an increase
in his circulating neutrophils. He became progressively hypothermic and his septic shock
worsened. An ultrasound of the hepatic artery showed that it was patent. Continuous renal
replacement therapy was started 4 days after admission. The patient gradually became
increasingly acidotic and hypotensive and died 7 days after admission. The patient was
given human intravenous immunoglobulin (IVIG) during his course because of a very low
measured serum IgG level. At the request of the transplant surgery service, he also received
a short course of high-dose solumedrol. Among candidate etiologic agents, sulfa and beta-
lactam antibiotics stood out: both of these had been started within the 3 weeks prior to the
patient’s presentation with TEN and both are known to be frequently implicated in TEN.1,2
DISCUSSION
This patient’s diagnosis may well have been TEN, and if so, this constitutes the first case
report of severe TEN following liver transplant in the United States. There are 2 previous
reports of TEN following liver transplant, one in the French literature3 and the other in-
volving a case of mild desquamation without mucous membrane involvement.4 Because
posttransplant GVHD bears such a strong clinical resemblance to TEN, GVHD is a diag-
nosis that must be maintained in the differential for all of these patients. Below, we review
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the clinical characteristics of both TEN and GVHD, illustrating the diagnostic ambiguity
in our patient’s case.
Toxic epidermal necrolysis was first recognized as a distinct clinical entity approx-
imately 50 years ago.5 It is characterized by what appears to be an autoimmune attack
on the patient’s epithelial surfaces within a few weeks of exposure to a new medication.
By definition, at least 30% of the total body surface area of the skin is involved. Other
commonly stricken surfaces are the conjunctivae and mucosae (airway, enteric, genitouri-
nary). The loss of skin and mucosal barriers leaves the patients prey to infection. Airway
complications are common and intubation for airway protection is often required. In its
most severe manifestation, TEN appears to cause bone marrow depression with resulting
leukopenia, anemia, and thrombocytopenia. Death in the TEN patient is usually a result of
septic shock/multiple organ failure.6
The epidemiology of TEN is reasonably uniform worldwide, striking about 1 person
per million per year. The syndrome is deadly, with the mortality rate ranging from 30%
to 60% depending on the population under study: the older patient, the patient with more
comorbidities,andthepatientwithasepticcomplicationismorelikelytodie.7 Aprognostic
multiparametricscoringsystemcalledSCORTENwasrecentlyelaboratedbyBastuji-Garin
and colleagues.8
Toxic epidermal necrolysis is preceded by toxin (medication) exposure, usually a new
medication that the patient has been taking for less than 1 month. Common culprits are the
nonsteroidal anti-inflammatory drugs, sulfa and beta-lactam antibiotics, and anticonvul-
sants, although there are case reports of hundreds of different medication exposures (even
steroids). External beam radiation therapy given with anticonvulsants appears to increase
the risk of TEN by 2 to 3 orders of magnitude9as does antiviral use by patients infected with
HIV .10
In the past several years, a link between the Fas ligand and Fas ligand receptor and
TEN has been posited.11,12 This hypothesis led to the introduction of IVIG (an inhibitor
of Fas ligand binding) as a treatment for TEN, and several series and case reports support-
ing the utility of IVIG treatment have been published.13,14 None of these is convincing,
and there is equally good evidence that IVIG does not appreciably affect the mortality of
the disease.15,16 Recent studies using lymphocytes derived from the blister fluid of TEN
patients suggest that the disease is mediated by CD8+ cytotoxic T cells that kill their ep-
ithelial cell targets by the perforin/granzyme mechanism17 and that the endangered basal
keratinocytes actually elaborate the Fas ligand in order to destroy the attacking CD8+ cells.
If these data prove repeatable, they may explain the clinical inadequacy of IVIG treatment.
Corticosteroids, another treatment used in the past, probably do not alter the progression
of TEN and increase the risk of infection.18,19 The current standard of care for TEN is
supportive.
Lack of a good animal model for TEN20 and the rarity of the syndrome have hampered
investigation of its etiology at the cellular level, but, as noted above, the syndrome appears
to be mediated by cytotoxic (CD8+)t h ymocytes. Consequently, the case reported here
is surprising. The patient had just had a liver transplant and had received antithymocyte
globulin as part of his immunosuppressive induction. Following the transplant, he was
taking 3 immunosuppressive medications. Nonetheless, within 3 weeks of starting Bactrim
pneumocystisprophylaxisandwithin1weekofstartingbeta-lactamantibioticshedeveloped
an illness indistinguishable clinically from TEN.
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Reviewing the patient’s laboratory studies after his death revealed that his lymphocyte
count began to increase about 3 weeks after his transplant and continued to increase as
a percentage of his total leukocytes even as his white blood cell count plummeted. At
the time he was most neutropenic, all of his circulating leukocytes were lymphocytes,
consistent with the hypothesis that his disease was CD8+ thymocyte mediated. We have
no evidence indicating whether the patient’s circulating CD8+ thymocytes were donor or
recipientlymphocytes.Ifthelymphocytesweredonorderived,thenthediagnosisofGVHD
would be more likely than TEN:
1. Although GVHD is commonly associated with marrow (or stem cell) transplants,21 it
is a known rare complication of orthotopic liver transplantation with an incidence of
somewhere between 0.1% and 1%. A liver transplant transfers up to 1 billion donor
leukocytes (T cells, monocyctes, natural killer cells) to the recipient.
2. Risk is significantly increased when the recipient and the donor share a major histocom-
patibility antigen haplotype,22 making the incidence of GVHD higher in living-related
donor liver transplants. Additional risk factors appear to be recipient age older than 65
years and a 40-year age difference between a younger donor and an older recipient.
3. GVHD usually occurs a few weeks (range 1–8 weeks) after transplant.
4. Initial symptoms are usually fever, diarrhea, and an erythematous macular rash.
5. Treatments have ranged from increased immunosuppression (to incapacitate the donor
lymphocytes:steroidsandantithymocyteglobulin)towithdrawalofimmunosuppression
(toallowrecipientlymphocytestokilldonorlymphocytes).Notreatmenthasbeenproven
effective and survival is poor (20% at most).
Most, but not all, cases of post–liver transplant GVHD are accompanied by diarrhea
secondary to cytotoxic T-cell attack on the gastrointestinal mucosa. TEN is also often
accompanied by immune destruction of gut epithelium. Our patient did not present with
diarrhea.Infact,oneofthenotableaspectsofhiscoursewasthathetoleratedtubefeedswell
and continued to have bowel movements until the last 2 days before he died. Demonstration
ofmacrochimerism(significantnumberofdonorlymphocytes)incirculatinglymphocytesis
necessaryforaconclusivediagnosisofGVHD.Thesedatawerenotavailableforourpatient
postmortem as the family declined autopsy. In the absence of such data, it is impossible to
differentiate between the diagnoses of TEN and GVHD in the weeks following orthotopic
livertransplantation.Unfortunately,correctlydistinguishingbetweenthese2clinicalentities
currently offers no advantage to the patient: there are no proven specific therapies for
either syndrome except the provision of supportive critical care. Future work may, however,
produceaspecifictherapyforeitherTENorGVHD.Giventheirsimilarclinicalpresentation
and their origin in CD8+ attack on epithelial surfaces, advances in the treatment of one of
these may give therapeutic insights into the other.
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